Why CRBU fell 48.9% on Oct 7 2026: program discontinuation
CRBU-48.9%on Wed Oct 7 2026
Caribou Biosciences, Inc. Common Stock was down 48.9% on the day at $0.5798, ranked #3 on 94.2× its usual five-minute volume, when TapeRank recorded this drop at 09:55 ET during regular hours.
THE DAY ON THE LIST · 1 EVENT
- 09:55 ETMOVER · REGULAR
$0.5798 · ▼ 48.9% ON THE DAY · 94.2× 5M RVOL · RANK #3
JUSTIFIEDCONFIDENCE5/5CRBU is down 49.3% after announcing a strategic-alternatives review, discontinuation of both lead CAR-T programs, and a substantial workforce reduction. The downgrades and $1 price-target cuts reinforce the repricing, while the restructuring indicates the company is shifting toward asset monetization or wind-down.
WHYA roughly 49% drop is large but proportionate to abandoning two clinical programs and restructuring the business, especially after the stock already fell 35% after hours.ANALYZED 09:55 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 09:55 ET
LAST0.5798DAY▼ 48.9%5 MIN▼ 2.87%5M RVOL94.2×5M $VOL$505KFLOAT*107.2MRANK#3SESSIONREGULARVWAP0.6194HOD0.7399LOD0.5460OR HIGH0.6551OR LOW0.5460PREV CLOSE1.14PM HIGH0.7399PM LOW0.5589GAP▼ 43.96%* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
THE SESSION
- 09:30 ETOpened at $0.6360, -44.0% on the previous close of $1.14
- 09:33 ETRegular-session low, $0.5460
- 10:55 ETRegular-session high, $0.6700
- 15:59 ETLast trade of the regular session, $0.6177, -45.6% on the previous close of $1.14
- Volume: 33.6M shares in regular hours, 3.1M before the open
CRBU opened at $0.6360 after Caribou Biosciences announced a strategic-alternatives review, discontinued its two lead CAR-T programs and cut its workforce; TapeRank read the news as justifying the move. The stock fell to $0.5460 by 09:33 ET, and TapeRank later ranked it #3 at $0.5798, down 48.9%, while downgrades and $1 price-target cuts reinforced the repricing. It recovered to a session high of $0.6700 at 10:55 ET before ending regular trading at $0.6177, still 45.6% below the previous close; there were no halts during the session.
WRITTEN THU OCT 15 2026 18:02 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- 09:48 ETRBC Capital Downgrades Caribou Biosciences to Sector Perform, Lowers Price Target to $1Benzinga
- 08:03 ETLeerink Partners Downgrades Caribou Biosciences to Market Perform, Lowers Price Target to $1Benzinga
- 01:34 ETCaribou Biosciences (CRBU) Shares Fall 35% After Hours: Here's WhyBenzinga
- TUE 16:20 ETTrading Halt: Halt status updated at 4:20:00 PM ET: Quotation Resumption: News and Resumption TimesBenzinga
- TUE 16:08 ETCaribou Biosciences Announces Strategic Alternatives Review, Discontinues Vispa-Cel And CB-011 CAR-T Programs, Cuts Workforce; Had $113.8M Cash At June 30Benzinga
- TUE 16:07 ETCaribou Biosciences Mulls Strategic Options To Maximize Shareholder Value; Intends To Discontinue Further Development Activities For Two Allogeneic CAR-T Cell Therapy ProgramsBenzinga
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list